GlassScriptPhysician profile
Cecilia C Bergh
NPI 1114134327
$13,698.81
in general payments reported to CMS, 2019-2025
43 companies · $2,367 in 2025
The $2,367 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,655 · 2020: $906 · 2021: $1,678 · 2022: $2,376 · 2023: $2,437 · 2024: $2,280 · 2025: $2,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,907 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,906.54 |
| Education | $176.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,459.84 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $2,282.57 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,059.12 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $786.85 | 2020-2025 | |
| Amgen INC. | $667.59 | 2021-2025 | Tezspire, Tavneos |
| Regeneron Healthcare Solutions, INC. | $656.54 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $622.88 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Novartis Pharmaceuticals Corporation | $572.54 | 2019-2025 | |
| Mylan Specialty L.P. | $498.85 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $464.85 | 2020-2025 | Glassia |
| Genentech USA, INC. | $412.39 | 2019-2025 | Xolair |
| Insmed, INC. | $367.26 | 2019-2024 | Arikayce |
| Paratek Pharmaceuticals, INC. | $313.62 | 2021-2024 | Nuzyra |
| United Therapeutics Corporation | $275.14 | 2020-2025 | Tyvaso, Tyvaso |
| Jazz Pharmaceuticals INC. | $241.02 | 2023-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $222.75 | 2019-2025 | Smartvest |
| Philips North America LLC | $180.59 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $159.79 | 2021-2024 | Acthar |
| Inspire Medical Systems, INC. | $145.66 | 2023-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $136.12 | 2021-2024 | Uptravi, Opsumit |
| Sunovion Pharmaceuticals INC. | $122.42 | 2019-2020 | |
| Vifor Pharma, INC. | $113.02 | 2024-2025 | Zemaira, Veltassa |
| Baxter Healthcare | $91.75 | 2023-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Teva Pharmaceuticals USA, INC. | $85.54 | 2020-2023 | Airduo Digihaler |
| Axsome Therapeutics, INC. | $70.10 | 2023-2025 | Sunosi |
| Pulmonx Corporation | $68.61 | 2023-2025 | Zephyr Delivery Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Verona Pharma, INC. | $68.34 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $62.01 | 2019-2023 | Belsomra |
| Abbvie INC. | $60.62 | 2021-2024 | |
| Shionogi INC | $58.43 | 2024 | Fetroja |
| Viatris Specialty LLC | $47.37 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $43.74 | 2019-2022 | |
| Shire North American Group INC | $35.57 | 2019 | |
| Atricure, INC. | $34.16 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Lilly USA, LLC | $32.65 | 2025 | Zepbound |
| Nabriva Therapeutics, Plc | $32.64 | 2021 | |
| Harmony Biosciences LLC | $31.82 | 2022 | |
| Ani Pharmaceuticals, INC. | $25.53 | 2023 | Purified Cortrophin Gel |
| Pharming Healthcare, INC. | $20.80 | 2023 | Ruconest |
| Advanced Respiratory, INC | $18.95 | 2019 | |
| Circassia INC. | $18.16 | 2019 | |
| Inogen, INC. | $17.04 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Allergan, INC. | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecilia Bergh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.